Navigation Links
ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
Date:4/9/2013

Cleveland, OH (PRWEB) April 09, 2013

Partnerships between industry and vendors are a positive trend for the drug discovery industry when the right companies come together, as they allow for innovation and also optimize the process to facilitate identifying the right drugs faster and more effectively. On Friday, May 10th, 2013, ChanTest will host its second User Meeting: Partnerships in Drug Discovery. The User Meeting will be held in South San Francisco, California at the Westin San Francisco Airport, 1 Old Bayshore Highway, Millbrae, CA 94030.

This complimentary event highlights the latest advances and strategies for Ion channel and GPCR screening, along with profiling for drug discovery and preclinical cardiac safety testing. “The second ChanTest User Meeting: Partnerships in Drug Discovery will bring together users and partners, present new offerings, project news and coordinate future developments,” said Chris Mathes, Ph.D., Chief Commercial Officer.

Click here to register.

This year’s keynote speaker will be Dr. Philip Sager, Chair of the Scientific Committee, Cardiac Safety Research Consortium. He will speak on “Preclinical and Clinical Development”. The event is co-sponsored by Axion Biosystems, Cellular Dynamics International, ACEA Biosciences, Sophion and Molecular Devices.

Friday, May 10, 2013
2nd ChanTest User Meeting: Partnerships in Drug Discovery
Westin San Francisco Airport
1 Old Bayshore Highway
Millbrae, CA 94030

Register

FURTHER INFORMATION

ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past several years. ChanTest is based in Cleveland, Ohio.

Visit http://www.chantest.com to learn more about what we do.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10612289.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican
3. Probiotic Action Announces New Edible Probiotic Trend
4. Core and More Technologies Announces the Most Comprehensive and Cost-effective Paid Search Advertising Packages Available in the Industry Today
5. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
6. Probiotic Action Announces New Use for Their Adult Acne Treatment and Explains its Beauty Benefits for Women
7. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
8. ACC Clean Energy Challenge Announces Elite Eight Plus Two, Will Vie to Reach Final Four
9. Seahorse Bioscience Announces AACR Travel Award Recipients
10. Bio-IT World Announces Best of Show Awards Finalists for the Bio-IT World Conference & Expo
11. LamdaGen Corporation Announces Japan Patent Issuance for Enzymatic Diagnostic Assays on Plasmonic Nano-Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for any ... So which eye do you rinse first if a dangerous substance enters both eyes? It’s ... Wash with its unique dual eye piece. , “Whether its dirt and debris, or ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):